Evaluation of vancomycin individualized model-based dosing approach in neonates

Background: Vancomycin is commonly used to treat methicillin-resistant staphylococcal infections in neonates. Consensus on its ideal dosing in neonates has not been achieved. Model-based dosing recently has evolved as an important tool to optimize vancomycin initial dosing. The aim of this is to eva...

Full description

Saved in:
Bibliographic Details
Main Authors: Manal Abouelkheir, Abdullah Almohaizeie, Abdulrahman Almutairi, Sara Almuhisen, Saeed Alqahtani, Abdullah Alsultan
Format: Article
Language:English
Published: Elsevier 2023-05-01
Series:Pediatrics and Neonatology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1875957222002583
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849414581007417344
author Manal Abouelkheir
Abdullah Almohaizeie
Abdulrahman Almutairi
Sara Almuhisen
Saeed Alqahtani
Abdullah Alsultan
author_facet Manal Abouelkheir
Abdullah Almohaizeie
Abdulrahman Almutairi
Sara Almuhisen
Saeed Alqahtani
Abdullah Alsultan
author_sort Manal Abouelkheir
collection DOAJ
description Background: Vancomycin is commonly used to treat methicillin-resistant staphylococcal infections in neonates. Consensus on its ideal dosing in neonates has not been achieved. Model-based dosing recently has evolved as an important tool to optimize vancomycin initial dosing. The aim of this is to evaluate a population pharmacokinetic model-based approach in achieving the vancomycin therapeutic target of an AUC0-24 400 as recommended by the recent IDSA treatment guidelines. This model was implemented as a simple Excel calculator to individualize and optimize vancomycin initial dosing in neonates. Methods: An Excel calculator was developed using a previously published population pharmacokinetic model in neonates. It was evaluated using retrospectively retrieved data. For each patient, the initial empiric dose was calculated using the proposed Excel model and the most widely used neonatal dosing references. The probability of achieving the target AUC0–24 of >400 mg h/L using the model-based method was calculated and compared with that of the empiric doses using other references. Results: This analysis included 225 neonates. The probability of achieving the target AUC0–24 >400 was 89% using our model-based approach compared with 11%–59% using tertiary neonatal dosing references (p < 0.01 for all comparisons). Conclusion: These innovative personalized dosing calculators are promising to improve vancomycin initial dosing in neonates and are easily applicable in routine practices.
format Article
id doaj-art-6bfcbf2799d445e8a78a9ecd675156da
institution Kabale University
issn 1875-9572
language English
publishDate 2023-05-01
publisher Elsevier
record_format Article
series Pediatrics and Neonatology
spelling doaj-art-6bfcbf2799d445e8a78a9ecd675156da2025-08-20T03:33:46ZengElsevierPediatrics and Neonatology1875-95722023-05-0164332733410.1016/j.pedneo.2022.10.006Evaluation of vancomycin individualized model-based dosing approach in neonatesManal Abouelkheir0Abdullah Almohaizeie1Abdulrahman Almutairi2Sara Almuhisen3Saeed Alqahtani4Abdullah Alsultan5Department of Clinical Pharmacy, College of Pharmacy, Misr International University, Cairo, EgyptPharmaceutical Care Division, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi ArabiaDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia; Department of Pharmaceutical Care, Prince Sultan Military Medical City, Riyadh, Saudi ArabiaDepartment of Clinical Pharmacy, King Fahad Medical City, Riyadh, Saudi ArabiaDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi ArabiaDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia; Corresponding author.Background: Vancomycin is commonly used to treat methicillin-resistant staphylococcal infections in neonates. Consensus on its ideal dosing in neonates has not been achieved. Model-based dosing recently has evolved as an important tool to optimize vancomycin initial dosing. The aim of this is to evaluate a population pharmacokinetic model-based approach in achieving the vancomycin therapeutic target of an AUC0-24 400 as recommended by the recent IDSA treatment guidelines. This model was implemented as a simple Excel calculator to individualize and optimize vancomycin initial dosing in neonates. Methods: An Excel calculator was developed using a previously published population pharmacokinetic model in neonates. It was evaluated using retrospectively retrieved data. For each patient, the initial empiric dose was calculated using the proposed Excel model and the most widely used neonatal dosing references. The probability of achieving the target AUC0–24 of >400 mg h/L using the model-based method was calculated and compared with that of the empiric doses using other references. Results: This analysis included 225 neonates. The probability of achieving the target AUC0–24 >400 was 89% using our model-based approach compared with 11%–59% using tertiary neonatal dosing references (p < 0.01 for all comparisons). Conclusion: These innovative personalized dosing calculators are promising to improve vancomycin initial dosing in neonates and are easily applicable in routine practices.http://www.sciencedirect.com/science/article/pii/S1875957222002583PharmacokineticsVancomycinNeonatesPharmacodynamics
spellingShingle Manal Abouelkheir
Abdullah Almohaizeie
Abdulrahman Almutairi
Sara Almuhisen
Saeed Alqahtani
Abdullah Alsultan
Evaluation of vancomycin individualized model-based dosing approach in neonates
Pediatrics and Neonatology
Pharmacokinetics
Vancomycin
Neonates
Pharmacodynamics
title Evaluation of vancomycin individualized model-based dosing approach in neonates
title_full Evaluation of vancomycin individualized model-based dosing approach in neonates
title_fullStr Evaluation of vancomycin individualized model-based dosing approach in neonates
title_full_unstemmed Evaluation of vancomycin individualized model-based dosing approach in neonates
title_short Evaluation of vancomycin individualized model-based dosing approach in neonates
title_sort evaluation of vancomycin individualized model based dosing approach in neonates
topic Pharmacokinetics
Vancomycin
Neonates
Pharmacodynamics
url http://www.sciencedirect.com/science/article/pii/S1875957222002583
work_keys_str_mv AT manalabouelkheir evaluationofvancomycinindividualizedmodelbaseddosingapproachinneonates
AT abdullahalmohaizeie evaluationofvancomycinindividualizedmodelbaseddosingapproachinneonates
AT abdulrahmanalmutairi evaluationofvancomycinindividualizedmodelbaseddosingapproachinneonates
AT saraalmuhisen evaluationofvancomycinindividualizedmodelbaseddosingapproachinneonates
AT saeedalqahtani evaluationofvancomycinindividualizedmodelbaseddosingapproachinneonates
AT abdullahalsultan evaluationofvancomycinindividualizedmodelbaseddosingapproachinneonates